Abstract:Circulation: Genomic and Precision Medicine, Ahead of Print. Background:Predictive performance of polygenic risk scores (PRS) varies across populations. To facilitate equitable clinical use, we developed PRS for coronary heart disease (CHD; PRSCHD) for 5 genetic ancestry groups.Methods:We derived ancestry-specific and multi-ancestry PRSCHDbased on pruning and thresholding and continuous shrinkage priors (polygenic risk score for CHD developed using ancestry-based continuous shrinkage methods) applied to summary statistics from the largest multi-ancestry genome-wide association study meta-analysis for CHD to date, including 1.1 million participants from 5 major genetic ancestry groups. Following training and optimization in the Million Veteran Program, we evaluated the best-performing PRSCHDin 176 988 individuals across 9 diverse cohorts.Results:Multi-ancestry polygenic risk score for CHD developed using pruning and thresholding methods and polygenic risk score for CHD developed using ancestry-based continuous shrinkage methods outperformed ancestry-specific Polygenic risk score for CHD developed using pruning and thresholding methods and polygenic risk score for CHD developed using ancestry-based continuous shrinkage methods across a range of tuning values. Two best-performing multi-ancestry PRSCHD(ie, polygenic risk score for CHD developed using pruning and thresholding methods optimized using a multi-ancestry population and polygenic risk score for CHD developed using ancestry-based continuous shrinkage methods optimized using a multi-ancestry population) and 1 ancestry-specific (PRSCSxEUR) were taken forward for validation. Polygenic risk score for CHD developed using pruning and thresholding methods (PT) optimized using a multi-ancestry population demonstrated the strongest association with CHD in individuals of South Asian genetic ancestry and European genetic ancestry (odds ratio per 1 SD [95% CI, 2.75 [2.41–3.14], 1.65 [1.59–1.72]), followed by East Asian genetic ancestry (1.56 [1.50–1.61]), Hispanic/Latino genetic ancestry (1.38 [1.24–1.54]), and African genetic ancestry (1.16 [1.11–1.21]). Polygenic risk score for CHD developed using ancestry-based continuous shrinkage methods optimized using a multi-ancestry population showed the strongest associations in South Asian genetic ancestry (2.67 [2.38–3.00]) and European genetic ancestry (1.65 [1.59–1.71]), lower in East Asian genetic ancestry (1.59 [1.54–1.64]), Hispanic/Latino genetic ancestry (1.51 [1.35–1.69]), and the lowest in African genetic ancestry (1.20 [1.15–1.26]).Conclusions:The use of summary statistics from a large multi-ancestry genome-wide meta-analysis improved the performance of PRSCHDin most ancestry groups compared with single-ancestry methods. Despite the use of one of the largest and most diverse sets of training and validation cohorts to date, improvement of predictive performance was limited in African genetic ancestry. This highlights the need for larger Genome-wide association study datasets of underrepresented populations to enhance the performance of PRSCHD.

Integration of biomarker polygenic risk score improves prediction of coronary heart disease in UK Biobank and FinnGen

Circulating Fatty Acids, Genetic Susceptibility and Hypertension: a Prospective Cohort Study

Integration of a polygenic score into guideline-recommended prediction of cardiovascular disease

Polygenic Risk, Rare Variants, and Family History: Independent and Additive Effects on Coronary Heart Disease

Minimal improvement in coronary artery disease risk prediction in Chinese population using polygenic risk scores: Evidence from the China Kadoorie Biobank

Pan-cancer analysis demonstrates that integrating polygenic risk scores with modifiable risk factors improves risk prediction

Assessment of the clinical utility of adding common single nucleotide polymorphism genetic scores to classical risk factor algorithms in coronary heart disease risk prediction in UK men

Polygenic and clinical risk scores and their impact on age at onset and prediction of cardiometabolic diseases and common cancers

Cardiovascular risk prediction using metabolomic biomarkers and polygenic risk scores: a cohort study and modelling analyses

Machine Learning Prediction of Biomarkers from SNPs and of Disease Risk from Biomarkers in the UK Biobank

Incremental Prognostic Value of a Coronary Heart Disease Polygenic Risk Score in Type 2 Diabetes

Combining European Society of Cardiology and American College of Cardiology/American Heart Association risk prediction model with polygenic risk scores to refine cardiovascular prevention

Assessing the value of incorporating a polygenic risk score with non-genetic factors for predicting breast cancer diagnosis in the UK Biobank

Integration of risk factor polygenic risk score with disease polygenic risk score for disease prediction

Identifying and characterizing disease subpopulations that most benefit from polygenic risk scores

Multi-Ancestry Polygenic Risk Score for Coronary Heart Disease Based on an Ancestrally Diverse Genome-Wide Association Study and Population-Specific Optimization

Clinical use of polygenic risk scores for detection of peripheral artery disease and cardiovascular events

Integrated Health-Related Phenotype by Polygenic Risk Scores Stratifies Risk Population for All-Cause Mortality: A Cohort Study Based on UK Biobank

Development of a Polygenic Risk Score to Improve Detection of Peripheral Artery Disease

Joint association between education and polygenic risk score for incident coronary heart disease events: a longitudinal population-based study of 26 203 men and women